<DOC>
	<DOCNO>NCT03009682</DOCNO>
	<brief_summary>This study single arm , multi-center phase II study olaparib monotherapy patient relapse small cell lung cancer ( SCLC ) harbor BRCA 1/2 mutation , ATM deficiency MRE11A mutation second third line chemotherapy . Target subject population : Patients small cell lung cancer progress follow first-line platinum-based therapy . Patients must image confirm progression 1st line chemotherapy SCLC treatment , must contain platinum-based regimen , least one measurable lesion per RECIST 1.1 .</brief_summary>
	<brief_title>Olaparib Monotherapy Relapsed Small Cell Lung Cancer Patients With BRCA 1/2 Mutations , ATM Deficiency MRE11A Mutations</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Histologically confirm SCLC document BRCA1 BRCA2 mutation , ATM deficiency MRE11A mutation . 3 . Small cell lung cancer progress firstline therapy . The 1st line regimen must contain platinum base regimen . Refractory firstline chemotherapy relapse within 6 month since last dose firstline chemotherapy If patient correspond sensitive relapse ( relapse 6 month since last dose firstline chemotherapy ) , she/he get second line treatment . 4 . Patients ( male/female ) must &gt; 20 year age . 5 . Patients must normal organ bone marrow function measure within 28 day prior administration study treatment define : 6 . ECOG performance status 01 7 . Patients must life expectancy â‰¥ 16 week 8 . Evidence nonchildbearing status woman childbearing potential : negative urine serum pregnancy test within 28 day study treatment , confirm prior treatment day 1 9 . Patient willing able comply protocol duration study include undergoing treatment schedule visit examination include follow . 10 . At least one lesion , previously irradiate , 11 . Provision inform consent genetic research . 1 . Involvement plan and/or conduct study ( applies AstraZeneca staff and/or staff study site ) 2 . Previous enrolment present study 3 . Participation another clinical study investigational product last 2 week ( long period depend defined characteristic agent use ) . 4 . Any previous treatment PARP inhibitor , include olaparib . 5 . More two prior chemotherapy regimen treatment small cell lung cancer . Pazopanib maintenance immune checkpoint inhibitor ( CTLA4 , PD1 PDL1 monoclonal antibody ) consider line treatment . 6 . Patients second primary cancer 7 . Patients receive systemic chemotherapy , radiotherapy ( except palliative reason ) , within 2 week last dose prior study treatment ( long period depend defined characteristic agent use ) . The patient receive stable dose bisphosphonates denosumab bone metastasis , study long start least 4 week prior treatment study drug . 8 . Concomitant use know CYP3A4 inhibitor ketokonazole , itraconazole , ritonavir , indinavir , saquinavir , telithromycin , clarithromycin nelfinavir 9 . Persistent toxicity ( &gt; =CTCAE grade 2 ) exception alopecia , cause previous cancer therapy . 10 . Resting ECG QTc &gt; 470msec 2 time point within 24 hour period family history long QT syndrome . 11 . Patients myelodysplastic syndrome/acute myeloid leukaemia 12 . Patients symptomatic uncontrolled brain metastasis . 13 . Major surgery within 14 day start study treatment patient recover effect major surgery 14 . Patients consider poor medical risk due serious , uncontrolled medical disorder , nonmalignant systemic disease active , uncontrolled infection . 15 . Patients unable swallow orally administer medication patient gastrointestinal disorder likely interfere absorption study medication . 16 . Breast feeding woman 17 . Immunocompromised patient , 18 . Patients know active hepatic disease ( i.e. , Hepatitis B C ) due risk transmit infection blood body fluid . 19 . Patients know hypersensitivity olaparib excipients product . 20 . Patients uncontrolled seizure .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>